Albany, NY -- (SBWIRE) -- 03/05/2019 -- Blepharitis - Epidemiology and Market Forecast-2028

05 Mar. 19

Blepharitis is estimated to affect more than 180 million people in the United States.

1. Although blepharitis is one of the most common ocular disorders.
2. 86% of all patients with dry eyes have concomitant blepharitis.
3. It affects both male and female equally but compared with other forms of blepharitis, patients affected by staphylococcal blepharitis are mostly female.

(Albany, US) DelveInsight launched a new report on Blepharitis - Market Insights, Epidemiology and Market Forecast-2028

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Blepharitis market
2. It organizes sales and marketing efforts by identifying the best opportunities for Blepharitis market
3. It helps to understand the future market competition in the Blepharitis market.

"Blepharitis, if not recognized and appropriately managed, can lead to worsening of signs and symptoms: disrupted pre-ocular tear film, discomfort and changes in visual function and negative effect on patient's quality of life."

Request for sample pages

Blepharitis is a long-term (chronic) condition, it can't usually be cured, but the symptoms can be controlled with good eyelid hygiene. Depending on the severity of the disease, one or multiple therapeutic treatments are utilized.

Currently, there is no US Food and Drug Administration approved therapies for Blepharitis. Treatment generally includes warm compresses, eyelid cleansing, antibiotics (topical, systemic) and topical anti-inflammatory agents (e.g. corticosteroids, cyclosporine) etc. These treatments are also used in combination. Topical antibiotics have been shown to provide symptomatic relief, and they have been effective in decreasing bacteria form the eyelid margin in the cases of anterior Blepharitis. The use of oral tetracycline antibiotics in Blepharitis is founded on small clinical trials that show their efficacy in improving symptoms of ocular rosacea and improving tear production and stability in patients with rosacea and meibomian gland dysfunction. Topical antibiotic ointments with or without corticosteroids or oral antibiotics can also be used effectively in the treatment of Blepharitis.

Costly new technologies (including devices using thermal pulsation) are available, but the current evidence is not sufficient to support their use in the treatment of Blepharitis. Also, in patients with chronic Blepharitis that does not respond to therapy, the possibility of carcinoma should be considered, particularly if associated with a loss of eyelashes. Thus, early diagnosis and appropriate treatment can prevent disfigurement and may be lifesaving for this condition.

Overall, the global Blepharitis therapeutics market is further expected to increase by the major drivers such as rising prevalent population, technological advancements and upcoming therapies in the forecast period [2019-2028].

Companies covered
1. InSite Vision
2. Nicox S.A
3. SUN PHARMA
And many others

Drugs covered
1. ISV-305
And many others

Table of contents
1. Report Introduction
2. Blepharitis Market Overview at a Glance
3. Blepharitis Disease Background and Overview
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Blepharitis Total Prevalent/ Incident Patient Population in 7MM
4.3. Blepharitis Total Prevalent Patient Population in 7MM– By Countries
5. Blepharitis Epidemiology by Countries
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
6. Current Treatment & Medical practices
7. Unmet Needs of the Blepharitis
8. Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Pipeline Therapies– At a glance
10. Key Cross Competition
11. Emerging Therapies for Blepharitis
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Blepharitis 7MM Market Analysis
12.1. 7MM Market Size of Blepharitis
12.2. 7MM Percentage Share of drugs marketed for Blepharitis
12.3. 7MM Market Sales of Blepharitis by Products
13. Blepharitis Market Analysis
13.1. United States
13.2. EU-5
13.2.1. Germany
13.2.2. France
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.3. Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight